Abstract
Background: Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal tissues of the oral cavity. Its pathogenesis involves immune dysregulation, angiogenesis, and psychological stress. Identifying reliable biomarkers can enhance diagnosis, monitor disease progression, and guide personalized treatment strategies. This study aimed to investigate five key serum biomarkers in OLP patients, including angiopoietin-2 (Ang-2), vitamin D, IgA, IgG, and cortisol, to explore their associations with disease severity.
Methods: This observational, case-control study enrolled 100 OLP patients and 80 healthy controls. The OLP patients were classified into three subtypes: reticular (n = 30), atrophic (n = 35), and erosive (n = 35). Fasting blood samples were collected, and serum levels of Ang-2, vitamin D, IgA, IgG, and cortisol were measured using ELISA, HPLC, immunoturbidimetry, and chemiluminescent immunoassays. Statistical analyses, including t-tests, ANOVA, and Pearson correlation, were performed to assess biomarker levels and their correlations with disease severity.
Results: Ang-2, IgA, and IgG levels were significantly elevated in OLP patients, particularly in the erosive subtype (P < 0.001), with positive correlations between these markers and disease severity. Vitamin D and cortisol levels were significantly reduced in OLP patients compared to controls (P < 0.01) and showed negative correlations with disease severity. These findings indicate the role of vascular, immune, metabolic, and stress-related factors in OLP pathogenesis.
Conclusion: Ang-2, vitamin D, IgA, IgG, and cortisol are valuable biomarkers for assessing OLP severity and guiding personalized treatment. Monitoring these biomarkers can aid in diagnosing OLP, tracking disease progression, and optimizing therapeutic strategies.
Keywords
Array
Array
Array
Array
Array
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.